Isotechnika Pharma Inc IPHAF

RE: Belatacept discussion

[labumba]

Naomi 2,

The company did give shareholders some perspective  about other alterative therapies in the market. Seeing Belatacept is still a novel drug in a drug development process. ISA couldn't comment or point out a particular novel drug. Nevertheless, ISA did emphasize both on a market analysis paper and in its past web caste  that biologics class does have some serious  issues like the drug cost, inconvenience to patients in terms of drug administration, and very susceptible to infections and infectious diseases.